替格瑞洛联合阿司匹林对糖尿病合并动脉粥样硬化患者肢体结局的影响
本研究为THEMIS随机对照试验的事后分析,纳入19,220例2型糖尿病合并冠心病患者,随机接受替格瑞洛或安慰剂叠加阿司匹林治疗,中位随访3年。结果显示替格瑞洛显著降低肢体事件风险(1.6% vs 1.3%;HR 0.77;95%CI 0.61-0.96;P=0.022),但增加出血。
要点
- 替格瑞洛降低肢体事件风险,包括血运重建和急性肢体缺血
- 基线有外周动脉疾病者肢体事件风险显著更高
- 获益与是否合并外周动脉疾病无关,但需权衡出血风险
核心结论
- 在2型糖尿病合并动脉粥样硬化患者中,替格瑞洛联合阿司匹林可降低肢体事件风险,但增加出血风险。
研究设计与样本
- THEMIS随机对照试验的事后分析,19,220例患者随机接受替格瑞洛或安慰剂叠加阿司匹林,中位随访3年。
主要发现
- 安慰剂组中,基线有外周动脉疾病者较无外周动脉疾病者MACE风险更高(10.7% vs 7.3%;HR 1.48;P<0.001),肢体事件风险也更高(9.5% vs 0.8%;HR 10.67;P<0.001)。
- 替格瑞洛组肢体事件发生率为1.6%,安慰剂组为1.3%(HR 0.77;95%CI 0.61-0.96;P=0.022)。
- 替格瑞洛显著降低血运重建风险(HR 0.79;95%CI 0.62-0.99;P=0.044)和急性肢体缺血风险(HR 0.24;95%CI 0.08-0.70;P=0.009)。
- 肢体事件获益与是否合并外周动脉疾病无关(有PAD:HR 0.80;95%CI 0.58-1.11;无PAD:HR 0.76;95%CI 0.55-1.05;Pinteraction=0.81)。
- 替格瑞洛对MACE(Pinteraction=0.40)和TIMI大出血(Pinteraction=0.3239)的影响未受外周动脉疾病状态修饰。
临床怎么用
- 对于2型糖尿病合并动脉粥样硬化患者,替格瑞洛联合阿司匹林可考虑用于降低肢体事件风险,但需评估出血风险。
- 外周动脉疾病患者肢体事件风险高,应加强监测和综合管理。
局限性
- 本研究为事后分析,外周动脉疾病基于基线报告,未来需专门针对外周动脉疾病患者(包括无冠心病者)的试验进一步明确获益风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ticagrelor reduced major adverse cardiovascular events (MACE) and increased bleeding in patients with type 2 diabetes mellitus (T2DM) and coronary artery disease. Limb events including revascularization, acute limb ischemia (ALI), and amputation are major morbidities in patients with T2DM and atherosclerosis. OBJECTIVES: This study sought to determine the effect of ticagrelor on limb events. METHODS: Patients were randomized to ticagrelor or placebo on top of aspirin and followed for a median of 3 years. MACE (cardiovascular death, myocardial infarction, or stroke), limb events (ALI, amputation, revascularization), and bleeding were adjudicated by an independent and blinded clinical events committee. The presence of peripheral artery disease (PAD) was reported at baseline. RESULTS: Of 19,220 patients randomized, 1,687 (8.8%) had PAD at baseline. In patients receiving placebo, PAD was associated with higher MACE (10.7% vs 7.3%; HR: 1.48; P < 0.001) and limb (9.5% vs 0.8%; HR: 10.67; P < 0.001) risk. Ticagrelor reduced limb events (1.6% vs 1.3%; HR: 0.77; 95% CI: 0.61-0.96; P = 0.022) with significant reductions for revascularization (HR: 0.79; 95% CI: 0.62-0.99; P = 0.044) and ALI (HR: 0.24; 95% CI: 0.08-0.70; P = 0.009). The benefit was consistent with or without PAD (HR: 0.80; 95% CI: 0.58-1.11; and HR: 0.76; 95% CI: 0.55-1.05, respectively; Pinteraction = 0.81). There was no effect modification of ticagrelor vs placebo based on PAD for MACE (Pinteraction = 0.40) or TIMI major bleeding (Pinteraction = 0.3239). CONCLUSIONS: Patients with T2DM and atherosclerosis are at high risk of limb events. Ticagrelor decreased this risk, but increased bleeding. Future trials evaluating the combination of ticagrelor and aspirin would further elucidate the benefit/risk of such therapy in patients with PAD, including those without coronary artery disease. (A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus [THEMIS]: NCT01991795).
引用
- Bonaca MP, Bhatt DL, Simon T, et al. Limb Outcomes With Ticagrelor Plus Aspirin in Patients With Diabetes Mellitus and Atherosclerosis. J Am Coll Cardiol. 2024. PMID: 38658101. doi:10.1016/j.jacc.2024.03.377
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。